Cocaine Use Disorder Market Outlook to Strengthen During the Forecast Period (2026-2036) with Emerging Therapies and Rising Healthcare Needs | DelveInsight
The cocaine use disorder market is expected to be driven by the anticipated introduction of emerging therapies including Mavoglurant (STP7; STALICLA), Metyrapone (EMB-001; Embera NeuroTherapeutics), TMP-301 (Tempero Bio), OMS527 (Omeros Corporation), AT-312 (Astraea Therapeutics), and others, advancements in treatment options, improved healthcare access, and a rising prevalence of the condition.
LAS VEGAS, Oct. 14, 2026 /PRNewswire/ -- Recently published Cocaine Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, cocaine use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Cocaine Use Disorder Market Summary
Discover FDA approved medication cocaine use disorder 2026 @ https://www.delveinsight.com/report-store/cocaine-use-disorder-market
Key Factors Driving the Growth of the Cocaine Use Disorder Market
Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said that the recent advances in understanding cocaine addiction have allowed researchers to identify promising new candidate drugs that can be effective pharmacological treatments for CUD.
Cocaine Use Disorder Market Analysis
Cocaine Use Disorder Competitive Landscape
Some of the cocaine use disorder drugs under development include Mavoglurant (STP7; STALICLA), Metyrapone (EMB-001; Embera NeuroTherapeutics), TMP-301 (Tempero Bio), OMS527 (Omeros Corporation), AT-312 (Astraea Therapeutics), and others.
STALICLA's Mavoglurant (STP7) is a selective non-allosteric antagonist of metabotropic glutamate receptor 5 (mGluR5), a key therapeutic target associated with addiction pathways, mood disorders, and neurodevelopmental conditions. By modulating glutamatergic signaling, mavoglurant is being developed to reduce cocaine craving by selectively inhibiting mGluR5 activity in the brain.
A Phase II clinical study demonstrated mavoglurant-induced abstinence in patients with cocaine use disorder (CUD) through mGluR5 inhibition, with no evidence of withdrawal liability. The company continues to advance STP7 (mavoglurant), having completed a Phase III-enabling drug–drug interaction study, with further development supported by the National Institute on Drug Abuse (NIDA) under the National Institutes of Health (NIH). In addition, the company plans to leverage its precision neurobiology drug development platform, DEPI, to identify subgroups of high-responder patients with rare and common neurodevelopmental disorders who may benefit from mavoglurant, based on findings from earlier clinical studies.
Embera NeuroTherapeutics' Metyrapone (EMB-001) is a novel combination therapy comprising metyrapone and oxazepam that is designed to modulate the stress-response system implicated in addiction and relapse. By targeting stress-, cue-, and drug-induced pathways, the therapy aims to reduce cocaine craving and help prevent relapse in patients with CUD.
EMB-001 has completed Phase I and Phase II clinical trials, with the Phase II study supported by NIDA under the NIH. However, publicly available clinical updates remain limited, and its progression into late-stage development has yet to be confirmed.
Tempero Bio's TMP-301 is an investigational negative allosteric modulator of mGluR5 designed to target glutamatergic pathways associated with addiction and relapse. Through modulation of this signaling pathway, TMP-301 is intended to reduce cocaine craving and help prevent relapse among patients with CUD.
The candidate has completed early-stage clinical evaluation, including a Phase I study assessing its safety profile and interaction with cocaine, and is progressing toward Phase II development. Supported by investor funding, TMP-301 represents an actively advancing and mechanistically targeted candidate within the relatively limited CUD therapeutic pipeline.
The anticipated launch of these emerging therapies are poised to transform the cocaine use disorder market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the cocaine use disorder market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the cocaine use disorder treatment market @ Cocaine Use Disorder Drugs
Cocaine Use Disorder Epidemiology Segmentation
The cocaine use disorder epidemiology section provides insights into the historical and current cocaine use disorder patient pool and forecasted trends for the leading markets. In 2025, gender-specific diagnosed prevalent cases of CUD across the 7MM showed a clear disparity, with approximately 70% of cases occurring in males and 30% in females.
The cocaine use disorder treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Cocaine Use Disorder Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Cocaine Use Disorder Market Size in 2025
USD 55 Million
Key Cocaine Use Disorder Companies
STALICLA, Embera NeuroTherapeutics, Tempero Bio, Omeros Corporation, Astraea Therapeutics, and others
Key Cocaine Use Disorder Therapies
Mavoglurant (STP7), Metyrapone (EMB-001), TMP-301, OMS527, AT-312, and others
Scope of the Cocaine Use Disorder Market Report
Download the report to understand the cocaine use disorder treatment pipeline @ Cocaine Use Disorder Clinical Trials
Table of Contents
1
Cocaine Use Disorder Market Key Insights
2
Cocaine Use Disorder Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
CUD Market Overview at a Glance
6.1
Emerging Landscape Analysis (By Phase, Molecule Type, and ROA)
6.2
Market Share (%) Distribution of CUD By Therapies in 7MM, in 2025
6.3
Market Share (%) Distribution of CUD By Therapies in 7MM, in 2036
7
Disease Background and Overview of CUD
7.1
Introduction to CUD
7.2
Signs and Symptoms
7.3
DSM 5 Criteria for Cocaine Use Disorder: Signs and Symptoms of CUD
7.4
Classification of CUD
7.5
Etiology
7.6
Risk Factors
7.7
Pathophysiology
7.8
Complications of Cocaine Use
7.9
Diagnosis
8
Management and Treatment
8.1
Non-pharmacological Treatment
8.2
Pharmacological Treatment
8.3
Treatment Guidelines
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationale
9.3
Total Diagnosed Prevalent Cases of CUD in the 7MM
9.4
The United States
9.4.1
Total Diagnosed Prevalent Cases of CUD in the US
9.4.2
Gender-specific Diagnosed Prevalent Cases of CUD in the US
9.4.3
Age-specific Diagnosed Prevalent Cases of CUD in the US
9.4.4
Severity-specific Diagnosed Prevalent Cases of CUD in the US
9.4.5
Total Treated Cases of CUD in the US
9.5
EU4 and the UK
9.6
Japan
10
Patient Journey
11
Emerging CUD Therapies
11.1
Competitive Landscape of Emerging Therapies
11.2
Mavoglurant (STP7/AFQ056): STALICLA
11.2.1
Product Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trial Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
EMB-001: Embera NeuroTherapeutics
12
CUD Market: 7MM Analysis
12.1
Key Findings
12.2
Cocaine Use Disorder Market Outlook
12.3
Conjoint Analysis
12.4
Key Cocaine Use Disorder Market Forecast Assumptions
12.5
Total Market Size of CUD in the 7MM
12.6
The United States Cocaine Use Disorder Market
12.6.1
Total Market Size of CUD in the United States
12.6.2
Market Size of CUD by Therapies in the United States
12.7
EU4 and the UK Cocaine Use Disorder Market
12.8
Japan Cocaine Use Disorder Market
13
KOL Views
14
SWOT Analysis
15
Unmet Needs
16
Market Access And Reimbursement
16.1
The United States
16.2
EU4 and the UK
16.3
Japan
16.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17
Bibliography
18
Cocaine Use Disorder Market Report Methodology
Related Reports
Cocaine Use Disorder Clinical Trial Analysis
Cocaine Use Disorder Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cocaine use disorder companies, including Embera NeuroTherapeutics, Novartis, Omeros Corporation, Indivior, Saniona, KemPharm, Kinoxis Therapeutics, Camino Pharma, EryDel, Astraea Therapeutics, and others.
Substance Use Disorder Market
Substance Use Disorder Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SUD companies including BioXcel Therapeutics, NFL Biosciences, STALICLA, Embera NeuroTherapeutics, PleoPharma, Kinnov Therapeutics, Imbrium Therapeutics, Atai Life Sciences, Beckley Psytech, and others.
Opioid Use Disorder Market
Opioid Use Disorder Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key OUD companies, including Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus, and others.
Alcohol Use Disorder Market
Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AUD companies, including Adial Pharmaceuticals, Eli Lilly and Company, MediciNova, Imbrium Therapeutics (subsidiary of Purdue Pharma), Altimmune, Tempero Bio, Nxera Pharma, The Pop Test & Palisades Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP